AN-NAJAH UNIVERSITY Pharmacolcgy 2 Dr. Adham Abu Taha Name:Jenan luboom Pharm-D 2 20-4-2011 - PowerPoint PPT Presentation

Loading...

PPT – AN-NAJAH UNIVERSITY Pharmacolcgy 2 Dr. Adham Abu Taha Name:Jenan luboom Pharm-D 2 20-4-2011 PowerPoint presentation | free to download - id: 5a3125-Nzc5N



Loading


The Adobe Flash plugin is needed to view this content

Get the plugin now

View by Category
About This Presentation
Title:

AN-NAJAH UNIVERSITY Pharmacolcgy 2 Dr. Adham Abu Taha Name:Jenan luboom Pharm-D 2 20-4-2011

Description:

Title: Vemovo general information Author: Abu Hadi Created Date: 4/15/2011 3:39:11 PM Document presentation format: On-screen Show (4:3) Other titles – PowerPoint PPT presentation

Number of Views:81
Avg rating:3.0/5.0
Slides: 11
Provided by: AbuH4
Category:

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: AN-NAJAH UNIVERSITY Pharmacolcgy 2 Dr. Adham Abu Taha Name:Jenan luboom Pharm-D 2 20-4-2011


1
AN-NAJAH UNIVERSITY Pharmacolcgy 2 Dr. Adham Abu
Taha NameJenan luboom Pharm-D 2 20-4-2011
2

Vimovo
3
Vimovo (naproxen esomeprazole) Company
AstraZeneca Approved April 2010
4
Therapeutic use Vimovo is specifically
indicated for the relief of signs and symptoms of
Osteoarthritis Rheumatoid arthritis
Ankylosing spondylitis
5
decrease the risk of developing gastric ulcers in
patients at risk of developing NSAID associated
gastric ulcers.
6
. The recommended initial dose is one tablet
twice daily. . Vimovo is to be taken at least
30 minutes before meals.
7
MOA Vimovo contains two different active
ingredients. Naproxen belongs to a group of
medications called (NSAIDs).   esomeprazole
belongs to a group of medications called proton
pump inhibitors (PPIs). Esomeprazole works by
binding to the proton pumps, stopping them from
producing acid. PPIs are very effective at
decreasing acid production, as they work directly
at the acid pumps.
8
 
  • Common side effect
  • Erosive gastritis -- in up to 19 percent of
    people
  • Indigestion or heart burn-- up to 18 percent
  • Gastritis -- up to 17 percent
  • Diarrhea -- up to 6 percent
  • Upper abdominal pain (stomach pain) -- up to 6
    percent

9
  • Contraindication
  • Patient with
  • Asthma
  • Liver disease
  • GI toxicity
  • Renal toxicity
  • Heart attack

10
Thank you
About PowerShow.com